Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer

Clinical Breast Cancer

Volumn 10, Issue 4, 2010, Pages 275-280

  Forero Torres, Andres ^a   Saleh, Mansoor ^b   Galleshaw, Janice ^b   Jones, Cheryl ^b   Shah, Jatin ^a   Percent, Ivor ^a   Nabell, Lisle ^a   Carpenter, John ^a   Falkson, Carla ^a   Krontiras, Helen ^a   Urist, Marshall ^a   Bland, Kirby ^a   De Los Santos, Jennifer ^a   Meredith, Ruby ^a   Caterinicchia, Valerie ^a   Bernreuter, Wanda ^c   O'Malley, Janis ^c   Li, Yufeng ^a   Lobuglio, Albert ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Georgia Cancer Specialists   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Antiangiogenesis; Monoclonal antibody; Sentinel lymph node biopsy; Tamoxifen; VEGF

Indexed keywords

BEVACIZUMAB; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AXILLARY LYMPH NODE; BLEEDING; BLOOD VESSEL OCCLUSION; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG TOLERANCE; DRY SKIN; ECHOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOMAGNESEMIA; INSOMNIA; MUSCULOSKELETAL PAIN; MYALGIA; PARESTHESIA; PHYSICAL EXAMINATION; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PROTEIN EXPRESSION; PROTEINURIA; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VAGINA BLEEDING; VAGINAL DRYNESS;

EID: 77955628590     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.035     Document Type: Article

References (26)

1. Mauri D, Pavlidis N, Ioannidis J. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:188-194
2. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24:1037-1044
3. Mathew J, Asgeirsson KS, Cheung KL, et al. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol 2009; 35:113-122
4. Jeruss JS, Mittendorf EA, Tucker SL, et al. Staging of breast cancer in the neoad-juvant setting. Cancer Res 2008; 68:6477-6481
5. Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91:2012-2017
6. Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoad-juvant chemotherapy in breast cancer. Surg Oncol 2008; 17:301-311
7. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on post-neoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100:1380-1388
8. Semiglazov V F, Semiglazov VV, Dashyan G, et al. Phase II randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007; 110:244-254
9. Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol 2006; 33:650-656
10. Seruga B, Tannock I F. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 2009; 27:840-842
11. The Arimidex. Tamoxifen, Alone or in Combination (ATAC) Trialists' Group: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC Trial. Lancet Oncol 2008; 9: 45-53.
12. Aesoy R, Sanchez BC, Norum JH, et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008; 6:1630-1638
13. Qu Z, Ginkel S V, Roy AM, et al. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res 2008; 68:6232-6240
14. Ryden L, Stendahl M, Jonsson H, et al. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat 2005; 89:135-143
15. Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18:1423-1431
16. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676-1688
17. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61:5407-5414
18. Barnadas A, Gil M, Sanchez-Rovira P, et al. Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anticancer Drugs 2008; 19:339-347
19. Traina TA, Rugo HS, Caravelli J F, et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 2010; 28:628-633
20. Torrisi R, Bagnardi V, Cardillo A, et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER-and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 2008; 99:1564-1571
21. Loges S, Mazzone M, Hohensinner P, et al. Silencing or fueling metastasis with VEGF inhibitors: anti-angiogenesis revisited. Cancer Cell 2009; 15:167-170
22. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239
23. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231
24. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98:1904-1913
25. Aghi M, Chiocca E. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 2005; 12:994-1005.
26. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843-850